|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400082846 |
|
最近更新日期: Date of Last Refreshed on: |
2024-04-09 16:31:39 |
|
注册时间: Date of Registration: |
2024-04-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
浮针联合膝舒胶囊治疗膝关节骨性关节炎的临床研究 |
|
Public title: |
Clinical study of Fu's Subcutaneous Needling combined with Xishu capsule in treatment of knee osteoarthritis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
浮针联合膝舒胶囊治疗膝关节骨性关节炎的临床研究 |
|
Scientific title: |
Clinical study of Fu's Subcutaneous Needling combined with Xishu capsule in treatment of knee osteoarthritis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘渝松 |
研究负责人: |
刘渝松 |
|
Applicant: |
Liu Yusong |
Study leader: |
Liu Yusong |
|
申请注册联系人电话: Applicant telephone: |
+86 13608386468 |
研究负责人电话:
Study leader's |
+86 13608386468 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
dr.liuyusong@163.com |
研究负责人电子邮件: Study leader's E-mail: |
dr.liuyusong@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区解放西路9号 |
研究负责人通讯地址: |
重庆市渝中区解放西路9号 |
|
Applicant address: |
9 Jiefang West Road, Yuzhong District, Chongqing |
Study leader's address: |
9 Jiefang West Road, Yuzhong District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆市中医骨科医院 |
||
|
Applicant's institution: |
Chongqing Orthopedic Hospital of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
重庆市中医骨科医院 |
||
|
Affiliation of the Leader: |
Chongqing Orthopedic Hospital of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
GKYYIRB2024005 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆市中医骨科医院伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Chongqing Orthopedic Hospital of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-01-09 00:00:00 | ||
|
伦理委员会联系人: |
漆国栋 |
||
|
Contact Name of the ethic committee: |
Qi Guodong |
||
|
伦理委员会联系地址: |
重庆市渝中区解放西路9号 |
||
|
Contact Address of the ethic committee: |
9 Jiefang West Road, Yuzhong District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 63931078 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
dr.77@foxmail.com |
|
研究实施负责(组长)单位: |
重庆市中医骨科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Chongqing Orthopedic Hospital of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区解放西路9号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
9 Jiefang West Road, Yuzhong District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重庆市卫健委和重庆市科委联合中医药科研项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Chongqing Health Commission and Chongqing Science and Technology Commission Joint TCM Research Proje |
||||||||||||||||||||||
|
研究疾病: |
膝关节骨性关节炎 |
||||||||||||||||||||||
|
Target disease: |
Knee osteoarthritis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究运用浮针联合膝舒胶囊治疗KOA,与常规电针联合膝舒胶囊治疗方案进行对比,通过观察治疗前后疼痛视觉模拟评分(visual analogue scale,VAS)、膝关节Lysholm评分表和血清TNF-α、IL-6、CRP含量的变化,来评估患者关节疼痛、功能活动、血清代谢指标的改善情况。肌骨超声在观察膝关节周围软组织改变的表现良好,通过肌骨超声来观察治疗前后患肌厚度、患肌表面肌筋膜的厚度以及膝关节积液的变化,以量化分析疗效。通过本研究拟探讨浮针治疗KOA的疗效及可能的作用机制,从而为浮针联合膝舒胶囊治疗KOA提供更多的实践依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
In this study, Fu's Subcutaneous Needling combined with Xishu capsule was used to treat KOA, and compared with conventional electroacupuncture combined with Xishu capsule, the changes of pain visual analogue scale (VAS), knee Lysholm scale and serum TNF-α, IL-6 and CRP contents before and after treatment were observed. To evaluate the improvement of joint pain, functional activity, and serum metabolic markers. Musculoskeletal ultrasound showed a good performance in observing the changes of soft tissues around the knee joint. Musculoskeletal ultrasound was used to observe the changes in the thickness of the affected muscle, the thickness of the surface myofascia of the affected muscle and the effusion of the knee joint before and after treatment, so as to quantitatively analyze the curative effect. This study aims to explore the therapeutic effect and possible mechanism of Fu's Subcutaneous Needling in the treatment of KOA, so as to provide more practical basis for Fu's Subcutaneous Needling combined with Xishu capsule in the treatment of KOA. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、符合上述中医和西医诊断标准,分级在I—III级 |
||||||||||||||||||||||
|
Inclusion criteria |
1. It meets the above diagnostic criteria for Chinese medicine and Western medicine and is graded at levels I-III; 2. age between 40 and 70 years old, gender unlimited; 3. No other treatment of KOA for at least 1 week before treatment (if other treatment has been received, a one-week washout period is required); 4. Confirm that the patient is primary knee osteoarthritis; 5. The patient's understanding, expression ability is normal, compliance is good, the patient or family members can cooperate with the score; 6. Agree to participate in my research and sign the informed consent. |
||||||||||||||||||||||
|
排除标准: |
1、不符合纳入标准者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Those who do not meet the inclusion criteria; 2. The skin around the knee joint is infected; 3. Patients with a history of rheumatism, rheumatoid arthritis, suppurative arthritis, etc; 4. Patients with serious life-threatening diseases of various systems; 5. Patients with acute infectious diseases or severe skin diseases; 6. At the same time with other mental illness diagnosis, such as personality disorders, schizophrenia, etc; 7. Pregnant or lactating women; 8. Take TCM allergy patients. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-05-01 00:00:00 至 To 2025-10-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由课题组成员运用SAS统计学软件的PROC PLAN 按1:1进行简单随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The members of the research group were simply randomized 1:1 by using the PROC PLAN of SAS statistical software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
对受试者、统计分析人员设盲 |
|
Blinding: |
Blinding subjects and statistical analysts |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
计划2026年1月1日左右上传网络数据平台。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
It is planned to upload the network data platform around January 1, 2026. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例记录表(CRF)进行数据采集,后续用相关文件进行数据的管理工作。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The data were collected using the Case Record Form (CRF), and then the relevant documents were used for data management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |